Esplugues De Llobregat

• A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy Pending
  2025-522949-22-00 5 Duchenne muscular dystrophy
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of In … Pending
  2025-523087-20-00 5 Duchenne muscular dystrophy
• The INFLUENCE Trial: Improve CAR T cell therapy by optimizing fludarabine exposure Pending
  2025-523096-34-00 5 B-cell Acute Lymphoblastic Leukemia
• A study to learn if fenfluramine hydrochloride is safe and works in people with Rett syndrome Pending
  2025-523157-34-00 5 Rett syndrome
• Study of MRM-3379 in Male Participants with Fragile X Syndrome Pending
  2025-523738-21-00 4 ​​Fragile X Syndrome​
• A study testing the medicine angiotensin II in patients of 0–17 years with a life-threateningly low blood pressure Pending
  2025-523750-14-00 5 refractory hypotension in distributive shock
• Improving Heart Scans in Children: A Study Comparing Two Contrast Agents for MRI Pending
  2025-524029-41-00 5 Cardiomyopathy, tetralogy of Fallot, or complex congenital heart disea
• Study to find out whether adding the medicine Naxitamab to standard treatment could help children and teenagers who have just been diagnosed … Pending
  2025-524140-35-00 4 Neuroblastoma or ganglioneuroblastoma (nodular or intermixed)
• Phase IV, randomized, open label, parallel groups clinical trial for evaluating the early Stop of antibiotic Treatment in high-risk febrile … Pending
  2025-524264-38-00 6 Infectious diseases
• An Open-label Study to evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in children with gMG Recruiting
  2025-520993-20-00 4 2026-05-19 Generalized Myasthenia Gravis
• Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Par … Recruiting
  2025-520988-41-00 4 2026-05-15 Immunoglobulin G4 related Disease (IgG4-RD)
• Safety, tolerability, pharmacokinetics, and efficacy of filgotinib for the treatment of polyarticular-course juvenile idiopathic arthritis i … Recruiting
  2024-511593-70-00 5 2026-04-27 Polyarticular-course juvenile idiopathic arthritis
• A study to learn more about how safe finerenone is, when it is taken for a longer time with standard treatment, in children and young adults … Recruiting
  2024-519830-22-00 5 2026-04-27 Heart failure due to systemic left ventricular systolic dysfunction
• A study for adolescents who are depressed and thinking of suicide Recruiting
  2024-518615-19-00 5 2026-04-22 Major Depressive Disorder
• A study to find out if BI 764198 helps adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS) Recruiting
  2025-522191-86-00 5 2026-04-02 Focal segmental glomerulosclerosis
• Pediatric Safety Follow-up Study of Prior Treatment with Romosozumab for Osteogenesis Imperfecta Recruiting
  2023-503293-21-00 5 2026-03-25 Osteogenesis Imperfecta
• A study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12 years with hemophilia A … Recruiting
  2025-521858-42-00 5 2026-03-16 Hemophilia
• A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRES … Recruiting
  2025-522170-36-00 5 2026-02-03 Diabetes Mellitus, Type 1
• A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (BARICADE-DELAY) Recruiting
  2025-521797-34-00 5 2026-01-20 Diabetes Mellitus, Type 1
• Phase III clinical trial to evaluate the efficacy and safety of specific immunotherapy with mannanconjugated allergoids for the treatment of … Recruiting
  2023-508547-51-00 5 2025-11-18 Aetiological treatment of moderate-to-severe allergic rhinitis/rhinoco
• A Study to Assess How Effective and Safe NVD003 is for Treating Patients with Congenital Pseudarthrosis of the Tibia. Recruiting
  2025-520998-39-00 5 2025-11-07 Congenital pseudarthrosis of the tibia
• A Phase 1-2, Double-Blind, MAD Study of ION440 in MDS Recruiting
  2023-507192-22-00 7 2025-10-24 Methyl CpG binding protein 2 (MECP2) Duplication Syndrome (MDS)
• A Phase 3 Open-Label Study to Investigate bexicaserin (LP352) in Children and Adults with Developmental and Epileptic Encephalopathy Recruiting
  2024-514974-39-00 5 2025-10-10 Developmental and Epileptic Encephalopathies (DEEs)
• The efficacy and safety of rilzabrutinib in participants aged 10 to 65 years with sickle-cell disease Recruiting
  2024-518645-17-00 5 2025-10-07 Blood and lymphatic diseases

Showing 25–48 of 317 trials